See more : Q4 Inc. (QFOR.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Access Bio, Inc. (950130.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Access Bio, Inc., a leading company in the industry within the sector.
- Dwarikesh Sugar Industries Limited (DWARKESH.BO) Income Statement Analysis – Financial Results
- Dillistone Group Plc (DSG.L) Income Statement Analysis – Financial Results
- India Tourism Development Corporation Limited (ITDC.BO) Income Statement Analysis – Financial Results
- Gratifii Limited (GTI.AX) Income Statement Analysis – Financial Results
- Zimmer Biomet Holdings, Inc. (ZIM.DE) Income Statement Analysis – Financial Results
Access Bio, Inc. (950130.KQ)
Website: https://accessbio.net
About Access Bio, Inc.
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 348.64B | 1,033.86B | 505.11B | 121.80B | 43.06B | 40.24B | 29.46B | 32.49B | 35.58B | 32.31B | 45.84B | 37.00B |
| Cost of Revenue | 178.38B | 214.10B | 108.72B | 31.05B | 33.65B | 24.65B | 20.32B | 18.42B | 23.90B | 16.75B | 21.98B | 15.24B |
| Gross Profit | 170.26B | 819.77B | 396.39B | 90.75B | 9.41B | 15.59B | 9.14B | 14.06B | 11.69B | 15.55B | 23.86B | 21.75B |
| Gross Profit Ratio | 48.84% | 79.29% | 78.48% | 74.51% | 21.85% | 38.75% | 31.03% | 43.29% | 32.85% | 48.14% | 52.05% | 58.80% |
| Research & Development | 16.08B | 7.32B | 4.89B | 4.01B | 2.20B | 2.93B | 1.94B | 1.51B | 970.71M | 814.73M | 415.20M | 326.20M |
| General & Administrative | 7.12B | 5.79B | 2.67B | 1.62B | 2.25B | 1.97B | 1.68B | 1.82B | 1.52B | 1.18B | 1.24B | 653.12M |
| Selling & Marketing | 163.52B | 311.62B | 42.53B | 5.28B | 4.63B | 5.82B | 4.76B | 3.84B | 3.92B | 7.39B | 8.07B | 10.36B |
| SG&A | 170.64B | 317.41B | 45.20B | 6.90B | 6.88B | 7.78B | 6.44B | 5.66B | 5.44B | 8.57B | 9.31B | 11.01B |
| Other Expenses | -38.05B | 25.44B | 86.17B | 11.13B | 8.36B | -283.69M | -209.49M | -54.49M | 1.65B | 160.93M | 59.95M | -23.78M |
| Operating Expenses | 148.67B | 350.16B | 136.27B | 22.04B | 17.45B | 20.97B | 16.00B | 14.76B | 11.68B | 13.15B | 12.48B | 13.24B |
| Cost & Expenses | 327.05B | 564.26B | 244.99B | 53.09B | 51.10B | 45.62B | 36.32B | 33.18B | 35.58B | 29.90B | 34.46B | 28.49B |
| Interest Income | 14.43B | 5.71B | 211.98M | 126.88M | 189.39M | 205.45M | 286.32M | 572.77M | 295.36M | 384.19M | 218.51M | 10.94M |
| Interest Expense | 3.71B | 6.23B | 3.35B | 1.87B | 2.19B | 1.81B | 1.71B | 508.92M | 31.76M | 56.34M | 56.32M | 940.43M |
| Depreciation & Amortization | 15.96B | 10.83B | 6.06B | 3.41B | 3.42B | 3.07B | 2.53B | 2.25B | 1.72B | 1.11B | 696.30M | 546.60M |
| EBITDA | 13.79B | 480.76B | 266.17B | 72.93B | -3.83B | -1.26B | -6.31B | 2.70B | 3.45B | 3.74B | 12.89B | 12.36B |
| EBITDA Ratio | 3.96% | 47.37% | 52.35% | 59.88% | -8.89% | -3.96% | -17.91% | 8.70% | 9.24% | 11.72% | 27.82% | 33.43% |
| Operating Income | 21.59B | 469.20B | 260.12B | 68.71B | -8.04B | -4.38B | -6.86B | -697.67M | 5.88M | 2.35B | 11.38B | 8.51B |
| Operating Income Ratio | 6.19% | 45.38% | 51.50% | 56.41% | -18.67% | -10.89% | -23.27% | -2.15% | 0.02% | 7.28% | 24.82% | 23.00% |
| Total Other Income/Expenses | -27.47B | -5.50B | -3.36B | -6.23B | -13.57B | -1.76B | -3.70B | 639.75M | 1.63B | 272.22M | 763.10M | 2.36B |
| Income Before Tax | -5.88B | 463.70B | 256.76B | 62.48B | -21.61B | -6.14B | -10.56B | -57.92M | 1.64B | 2.62B | 12.14B | 10.87B |
| Income Before Tax Ratio | -1.69% | 44.85% | 50.83% | 51.30% | -50.19% | -15.26% | -35.83% | -0.18% | 4.61% | 8.12% | 26.48% | 29.39% |
| Income Tax Expense | -580.48M | 113.95B | 66.68B | 14.67B | -955.35M | 243.84M | -1.35B | 1.09B | 1.17B | 742.90M | 4.30B | 3.42B |
| Net Income | -3.17B | 346.67B | 189.69B | 48.27B | -20.66B | -4.24B | -6.49B | 304.16M | 1.27B | 2.43B | 7.84B | 7.45B |
| Net Income Ratio | -0.91% | 33.53% | 37.55% | 39.63% | -47.97% | -10.54% | -22.01% | 0.94% | 3.56% | 7.53% | 17.10% | 20.14% |
| EPS | -91.00 | 10.05K | 5.33K | 1.43K | -725.82 | -165.00 | -249.00 | 12.00 | 45.00 | 74.00 | 329.00 | 451.00 |
| EPS Diluted | -91.00 | 9.21K | 5.13K | 1.39K | -725.82 | -165.00 | -249.00 | 12.00 | 45.00 | 74.00 | 307.00 | 428.00 |
| Weighted Avg Shares Out | 34.87M | 37.63M | 35.57M | 33.80M | 28.46M | 25.70M | 26.05M | 25.35M | 28.11M | 25.35M | 23.82M | 16.52M |
| Weighted Avg Shares Out (Dil) | 34.87M | 37.63M | 37.00M | 34.68M | 28.46M | 25.70M | 26.05M | 25.35M | 28.11M | 25.35M | 25.53M | 17.41M |
Source: https://incomestatements.info
Category: Stock Reports